Taking Aim at Healing Targets in IBDThe Role of JAK Inhibition
This activity is jointly provided by Global Education Group (Global) and Integritas Communications.
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
The educational design of this activity addresses the needs of gastroenterologists involved in the management of patients with inflammatory bowel disease (IBD).
Statement of Need
The burden of Crohn’s disease and ulcerative colitis is significant and wide-ranging, affecting approximately 1.6 to 1.8 million Americans, and 6·8 million persons worldwide.1,2 When poorly controlled, these inflammatory bowel diseases (IBDs) negatively affect patient quality of life, social activities, travel, and ability to work, leading to higher rates of absenteeism and permanent work disability.3,4 The prevalence of IBD has increased substantially in many regions from 1990 to 2017, which might pose a social and economic burden on governments and health systems in the coming years.2
Over the past 2 decades, the introduction of biologic therapies that target underlying disease processes has dramatically changed the treatment of IBD. Current biologic therapies have improved the treatment of IBD flares and maintenance of clinical remission. These agents are, however, limited by primary nonresponse and loss of response in a substantial proportion of patients, disease relapse after cessation of therapy, and adverse effects such as risk for infection and malignancy.5 As the pathogenesis and treatment of IBD are complex and variable, there is a need to better understand the underlying pathogenic mechanisms and develop drug therapies to target these mechanisms.5
During this program, faculty will engage in a discussion/debate-to-consensus format to provide expert insights into areas in which IBD clinical data or standard-of-care recommendations are evolving. Throughout the symposium, attendees will use iPads to complete a series of clinical challenges designed to highlight practical applications of faculty discussions.
- Dahlhamer JM, Zammitti EP, Ward BW, Wheaton AG, Croft JB. Prevalence of Inflammatory Bowel Disease Among Adults Aged >/=18 Years - United States, 2015. MMWR Morb Mortal Wkly Rep. 2016;65(42):1166-1169.
- GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17-30.
- Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Naim A, Lofland JH. The employee absenteeism costs of inflammatory bowel disease: evidence from US National Survey Data. J Occup Environ Med. 2013;55(4):393-401.
- Moradkhani A, Beckman LJ, Tabibian JH. Health-related quality of life in inflammatory bowel disease: psychosocial, clinical, socioeconomic, and demographic predictors. J Crohns Colitis. 2013;7(6):467-473.
- Coskun M, Vermeire S, Nielsen OH. Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci. 2017;38(2):127-142.
Upon completion of this activity, participants will be better able to:
- Employ tools to achieve appropriate risk-stratification and assessment of patients with IBD
- Discuss the unmet needs of patients with IBD
- Compare and contrast the clinical profiles of current and emerging Janus kinase (JAK) inhibitors in IBD
- Integrate concepts of behavioral science in shared decision-making with patients and the IBD care team balanced by the realities of differing health care systems and payers
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.
Physician Credit Designation
Global designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 2.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Fee Information & Refund/Cancellation Policy
There is no registration fee for attending this program, however, seating is limited. Preregistration does not guarantee seating. We recommend arriving at the symposium location early.
Americans With Disability Act
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact us prior to the live event at firstname.lastname@example.org.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or email@example.com.